Telotristat etiprate is an investigational oral agent for carcinoid syndrome now being studied in the TELESTAR clinical trial.

TELESTAR is a global Phase III clinical trial specifically designed for patients whose carcinoid syndrome is not adequately controlled by their current somatostatin analog therapy.

The TELESTAR trial

To learn more, contact us at:

1-855-897-0125 (US and Canada)
800-3000-2030 (International)

Be sure to include your country's exit
code, such as +00 for the EU

Interested in learning about a new clinical trial for carcinoid syndrome?

Watch the video

Inhibiting excessive serotonin—
a novel approach

Telotristat etiprate is an investigational oral agent that inhibits tryptophan hydroxylase (TPH), the key enzyme responsible for serotonin production.2-4 Reducing serotonin produced from functioning carcinoid NETs in this manner is intended to treat carcinoid syndrome and its associated diarrhea, frequent bowel movements, abdominal pain, and flushing.

Learn more about telotristat etiprate in carcinoid syndrome


  1. Robertson RG, Geiger WJ, Davis NB. Carcinoid tumors. Am Fam Physician. 2006;74:429-434. PMID: 16913162
  2. O’Dorisio TM, Phan AT, Langdon RM, et al. Relief of bowel-related symptoms with telotristat etiprate in octreotide refractory carcinoid syndrome: preliminary results of a double-blind, placebo-controlled multicenter study. J Clin Oncol. 2012;30(suppl; abstract 4085).
  3. Poncet G, Faucheron JL, Walter T. Recent trends in the treatment of well-differentiated endocrine carcinoma of the small bowel. World J Gastroenterol. 2010;16:1696-1706. PMID: 20380000
  4. Margolis KG, Stevanovic K, Li Z, et al. Pharmacological reduction of mucosal but not neuronal serotonin opposes inflammation in mouse intestine. Gut. 2013. doi:10.1136/gutjnl-2013-304901. PMID: 23749550

You are now leaving
to go to

You are now leaving

Lexicon Pharmaceuticals, Inc. does not review the information contained on the following website for content, accuracy, or completeness. Use of and access to the information is subject to the terms, limitations, and conditions set by the website producer. Lexicon Pharmaceuticals, Inc. makes no claims about the accuracy or any other aspect of the information contained on this website, nor does Lexicon Pharmaceuticals, Inc. endorse this website.